Pedicloryl

Quick links to important sections

Pedicloryl

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pedicloryl

Property Description
Active ingredient Triclofos (Triclofos sodium)
Form Oral solution or Syrup
Pharmacological class Sedative-hypnotic agent
Common purpose Inducing calmness and rest
Origin Synthetic

Pedicloryl is a synthetic pharmaceutical medicine classified as a sedative-hypnotic agent, which falls under the broader category of psycholeptics or Central Nervous System (CNS) depressants. Its core function is to facilitate the induction of rest and a state of calmness by chemically reducing overall brain activity. The formulation of Pedicloryl as a sweetened oral solution or syrup specifically addresses the needs of patients, such as pediatric patients, who require a palatable and easily consumed liquid form.

The medicine is a single-ingredient product designed to alleviate high levels of tension, excitability, and restlessness to promote controlled quietude. The drug is administered through the oral route. Pharmacological studies have clinically recognized the compound for its reliable sedative properties, affirming its role in managing acute excitability.


Pedicloryl Composition and General Purpose

The active component in Pedicloryl is Triclofos, most commonly utilized as the salt Triclofos sodium, which is dissolved in an aqueous vehicle. Triclofos functions as a prodrug, meaning it is inactive when consumed but is rapidly metabolized by the body into the potent compound trichloroethanol. This conversion is essential for the drug's activity, establishing its mechanism as distinct from directly active sedatives.

This necessary conversion of Triclofos into trichloroethanol is the definitive mechanism for the drug's effect, allowing the active metabolite to enhance inhibitory signals in the brain, thereby slowing nerve activity. The overarching purpose of this liquid formulation is to provide a flexible and reliable method for quickly achieving temporary relief from tension and excitability, supporting patients who require pharmacological assistance to achieve rest and quietude.

What side effects are possible with Pedicloryl?

Official Safety Profile of Pedicloryl (Triclofos Sodium)

The safety profile of Pedicloryl is based on adverse reactions and classifications documented in official government regulatory sources. These effects are formally categorized by the physiological systems they impact, such as Nervous System Disorders (e.g., drowsiness, dizziness, ataxia, mental confusion, hallucinations) and Gastrointestinal Disorders (e.g., nausea, vomiting, gastric irritation).


Documented Serious Adverse Reactions and Frequencies

Certain clinically critical adverse reactions are explicitly documented in regulatory safety texts. Reactions such as Respiratory Arrest, Respiratory Depression, Shock, and Anaphylaxis are classified with an Incidence Unknown frequency, highlighting their presence in the safety profile even when a precise rate is not established from data. Serious events may also include Convulsive Seizure, which is documented as a potential withdrawal symptom upon sudden cessation of prolonged use.


Safety Constraints and Population-Specific Notes

The medicine is contraindicated for use in individuals with pre-existing severe Hepatic disorder, Renal disorder, Serious heart disease, Arrhythmia, or Reduced respiratory function. These restrictions are based on the potential for exacerbating underlying conditions or interfering with the metabolism of the active ingredient. For the pediatric population, specific monitoring of heart rate, respiratory function, and oxygen saturation is required, as stated in official labeling.

Safety profiles also note that prolonged administration carries a risk of Drug Dependence, and its use may exacerbate the effects of co-administered Central Nervous System (CNS) depressants.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Pedicloryl, a central nervous system (CNS) depressant, presents with documented clinical manifestations that require immediate emergency attention. These signs, based on official regulatory labeling, typically include profound somnolence, deep sedation, and progressive respiratory depression, which can rapidly progress to a state of coma. Additional physiological presentations documented in overdose cases may involve hypothermia, pronounced hypotension, and the development of severe cardiac arrhythmias or tachycardia.

A significant overdose is officially classified as a potentially life-threatening emergency due to the high risk of central nervous system failure, culminating in respiratory arrest and acute circulatory collapse. The regulatory labeling explicitly mandates that any suspected overdose must be treated urgently. It is required to seek immediate medical attention or contact emergency services immediately if signs such as difficulty breathing, significant change in consciousness, or extreme drowsiness are observed.

Management described in regulatory documents is strictly symptomatic and supportive, as no specific antidote is known for the active metabolite. Overdose care necessitates continuous cardiac and respiratory monitoring and typically requires hospital observation. Special regulatory notes indicate an increased vulnerability and enhanced risk of severe depression in both pediatric and elderly patients, along with those individuals possessing underlying hepatic or renal impairment.

Therapeutic Uses of Pedicloryl

Pedicloryl, which is relevant in the therapeutic domain of Hypnotics and Sedatives, provides support that helps ease the overall symptom burden associated with acute tension and restlessness. The medicine is commonly used to help with symptom clusters such as profound restlessness, excessive agitation, and generalized tension.

This medication is applied in clinical settings that involve acute or disruptive symptom patterns, including transient insomnia, pre-procedural anxiety, and the need for sedation during non-painful diagnostic procedures like EEG. This supports the process of achieving a state of calmness, which may help patient composure when symptoms intensify.

“This supportive therapy may assist with the process of easing sleep onset and contributing to necessary stillness during medical evaluation.”

Quick Fact: Symptomatic Support for Acute Restlessness

Pedicloryl is commonly used when symptoms create noticeable functional strain, supporting the patient during episodes of heightened discomfort by easing manifestations like agitation and contributing to easing distress, which supports the patient's ability to achieve rest or clinical cooperation.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Pedicloryl (Triclofos sodium) use is strictly governed by regulatory criteria based on age, organ function, and pre-existing conditions documented in official labeling.

Absolute Non-Eligibility (Contraindications)

Use of the medicine is formally prohibited in individuals with known hypersensitivity to the active ingredient. It is strictly contraindicated for patients with marked or severe hepatic impairment (liver function) or marked or severe renal impairment (kidney function). Non-eligibility also extends to patients with severe cardiac disease, severe respiratory insufficiency, or the metabolic disorder Acute Intermittent Porphyria.

Age and Conditional Use Restrictions

The medicine is generally established for use in adults. However, use in the pediatric population is restricted: it is not recommended for general, routine use in children under 12 years of age, though it may be administered as a single dose for specific procedural sedation. Older adults require careful administration due to potential increased sensitivity.

Furthermore, the medicine is generally not recommended for pregnant or breastfeeding women, and caution is formally required for patients with a history of substance or alcohol abuse.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Pedicloryl (Triclofos) documents several classifications of interactions, primarily focusing on additive pharmacological effects and alterations in active metabolite exposure.


Documented Interaction Patterns

The most significant documented interaction is the additive CNS depressant effect that occurs with the co-administration of Pedicloryl and other Central Nervous System (CNS) depressants or Alcohol (Ethanol). This is a pharmacodynamic potentiation that increases the risk of profound sedation.

Metabolically, the active metabolite, trichloroethanol, is known to competitively inhibit the enzyme alcohol dehydrogenase (ADH), which officially reduces the body's rate of ethanol clearance and increases blood alcohol concentration. Concomitant use with Chloral hydrate is also restricted due to the combined exposure to the shared active metabolite.

Exposure and Clearance Considerations

Pedicloryl's metabolites interact with Coumarin-based Anticoagulants, such as Warfarin. A metabolite, trichloroacetic acid, is documented to displace the anticoagulant from plasma protein binding, officially increasing the unbound concentration and raising the risk of a hypoprothrombinemic response and hemorrhage.

Specific patient populations are also noted for heightened interaction risk. Patients with significant hepatic or renal impairment are at greater risk of severe interactions due to the maintained and increased systemic exposure of the active drug metabolites.

Mechanism of Action

How Pedicloryl Works

Metabolic Activation into Trichloroethanol

Pedicloryl (Triclofos) functions as a prodrug; the administered compound is rapidly metabolized in the body, primarily by the liver, into its pharmacologically active metabolite, trichloroethanol. This conversion is the crucial initial metabolic step, producing the molecule that modulates key central nervous system (CNS) pathways.

GABA Receptor-Mediated Signaling Modulation

The active metabolite, trichloroethanol, acts within domains involving inhibitory receptor signaling in the brain. It enhances the effects of the primary inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), by binding to the GABA-A receptor complex. This binding potentiates inhibitory signaling across the CNS, resulting in increased neuronal hyperpolarization.

Modulation of Neuronal Activity

The enhancement of inhibitory GABA signaling modulates pathways within the CNS that govern the overall level of neuronal activity. This enhanced inhibition of action potential firing results in reduced neuronal excitation, which contributes directly to the resulting central nervous system depression profile.

Dosage and Administration Information

Official Administration Instructions for Pedicloryl (Triclofos Sodium)

Pedicloryl is formulated as an oral solution or syrup, which dictates that the route of administration is strictly oral. The standard liquid strength is typically 500 mg per 5 mL, requiring accurate measurement before consumption.

Dosing and Scheduling

The dosage is highly dependent on the purpose of use and the patient's age, and must adhere to the regimen established by the prescribing authority:

  • Adult Hypnotic Use: The standard single nightly dose ranges from 1 gram (10 mL) to 2 grams (20 mL), taken once daily immediately before bedtime.
  • Sedative Use: A lower dose, such as 500 mg (5 mL), may be taken up to twice daily for general restlessness.
  • Pediatric Sedation: For non-painful diagnostic procedures, a single dose based on body weight, commonly between 30 mg/kg to 50 mg/kg, is given approximately 45 to 60 minutes prior to the procedure to ensure the onset of effect. The single pediatric dose is generally capped at 2 grams.

Administration Constraints and Duration

Official instructions mandate that Pedicloryl is intended for short-term treatment only, and prolonged administration must be avoided. If the medicine has been used for an extended duration, its discontinuation requires a gradual dosage reduction (tapering) to manage cessation. While the dose may be taken with or without food, its administration requires careful management in individuals with hepatic or renal disorders due to the drug’s metabolism and excretion pathway.

Recent Clinical Evidence

Pedicloryl: Recent Clinical Evidence

Research has evaluated the combination in individuals experiencing chronic, debilitating pain.


Summary of Initial Findings

Initial trials examined the effect of the drug, based on the hypothesis that it may influence two major pain signaling pathways simultaneously. The primary focus of these randomized studies was to assess the drug's effect on pain intensity and its overall safety profile.

The evaluation explored whether this approach was associated with a reduction in pain intensity scores. Across the main studies, findings regarding the change in pain scores varied. One study included a comparison of symptomatic relief to an established, single-agent treatment, though evidence remains limited.


Safety and Administration

Safety data from the trials described the drug's tolerability profile in the studied adult population. The trials evaluated the drug's effect using a 12-hour dosing interval.

Secondary exploratory analyses within the studies also examined quality of life metrics, including sleep disturbance. The study reports indicated that some individuals reported reduced sleep interference, though dedicated trials are needed to confirm any potential association. Long-term data from the studies are currently undergoing regulatory review. The total duration of the completed studies reviewed so far is six months.

Key Studies & References NCT06774625: Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars (Example of Trial Design)

Frequently Asked Questions (FAQ)

Common questions about Pedicloryl (FAQ)


Q: How long does it typically take before Pedicloryl is described as working?

According to official product information, the active form of the medicine is quickly metabolized in the body. The resulting active compound reaches its highest levels in the bloodstream in about one hour after the dose is taken. For specific uses, such as procedural sedation in children, the expected onset of effect is documented to occur within 30 to 60 minutes.


Q: How long does the effect of a single use of Pedicloryl usually last?

Pedicloryl is officially indicated as a short-acting agent. Official documents suggest that the duration of the intended calming or hypnotic effect is generally described as lasting between 7 to 12 hours. This duration is consistent with its use as a medicine intended to help with nighttime rest.


Q: Is it common to feel tired after using Pedicloryl?

Yes, official safety data classifies drowsiness as a common side effect associated with the medicine. This is expected because the drug is a central nervous system depressant. Other common nervous system effects documented include dizziness and mental confusion.


Q: Is Pedicloryl addictive or habit-forming?

Regulatory documentation includes a warning that prolonged administration carries a risk of developing drug dependence. To mitigate this risk, the medicine is only prescribed for short-term use. Official information also advises cautious use for individuals who have a history of alcohol or substance abuse.


Q: Is there a maximum number of days Pedicloryl should be used continuously?

The medicine is explicitly indicated for short-term treatment only due to the potential for dependence with longer use. While the definition may vary, some guidelines suggest that continuous hypnotic use should generally not exceed two weeks.


Q: Can Pedicloryl be used during pregnancy or while breastfeeding?

Official eligibility information states that Pedicloryl is generally not recommended for use by pregnant women or those who are breastfeeding. A healthcare provider can discuss the documented risks and benefits related to use during these periods.


Q: Can Pedicloryl affect the ability to drive or operate machinery?

Official warnings state that the medicine may cause side effects such as drowsiness or dizziness. The official warning indicates that due to the potential for these effects, caution must be exercised regarding driving or operating heavy machinery.


Q: What are the official recommendations regarding stopping the use of Pedicloryl?

Regulatory instructions mandate that if the medicine has been used for prolonged periods, its discontinuation requires a gradual dosage reduction, often called tapering. Abrupt cessation of use may result in withdrawal symptoms such as convulsive seizures.


Q: What should I do if I forget to use Pedicloryl?

For a missed dose intended for nighttime use, official guidance suggests skipping the missed dose entirely. It is advised in the labeling not to take the medicine at any other time of the day to help prevent issues like daytime drowsiness.


Q: Is Pedicloryl a controlled substance?

Yes, Pedicloryl is typically classified as a Schedule IV controlled substance in regulatory jurisdictions that utilize drug scheduling systems, such as the US. This classification is assigned based on its potential for dependence and misuse.


Q: Do you need a prescription to get Pedicloryl?

Yes, this medicine is classified as a prescription-only medicine (POM) in most official regulatory regions. It is not available for general purchase over-the-counter and requires a prescription from an authorized prescriber.


Q: Are there different strengths or versions of Pedicloryl available?

Official dosage forms primarily include the liquid (oral solution or syrup), commonly at a strength of 500 mg per 5 mL. In some regions, other forms like capsules or tablets may also be available, such as a 500 mg strength.


Q: Is there any research evidence on using Pedicloryl for long periods?

Pedicloryl is officially indicated only for short-term use. While clinical trials have been reviewed with durations up to six months, regulatory documents clearly state that prolonged administration is not recommended due to the associated risk of drug dependence.


Q: Does Pedicloryl show up on drug tests?

The drug is converted in the body into an active metabolite known as trichloroethanol. This metabolite, which is a potent compound, is detectable in certain drug screening protocols.


Q: What is the difference between Pedicloryl tablets and the liquid form?

Both the tablet and liquid (syrup) forms contain the same active ingredient, Triclofos sodium, for oral consumption. The liquid formulation is often preferred for those who have difficulty swallowing pills, such as pediatric patients.


Q: Why do some people say Pedicloryl makes them feel dizzy?

Dizziness is a documented side effect related to the drug's mechanism of action. The medicine enhances inhibitory signals in the brain, leading to an overall calming effect known as Central Nervous System (CNS) depression, which can cause feelings of dizziness or mental confusion.


Q: Where is the clinical evidence for Pedicloryl published?

Clinical evidence supporting the drug's use is documented in medical journals and scientific literature. Summaries and research references are often accessible via official sources, including publicly available databases like the National Library of Medicine (NIH).


Q: Is it normal if Pedicloryl causes a strange taste in the mouth?

Official safety data documents possible gastrointestinal disorders with this medicine, such as nausea or vomiting. However, official safety data on adverse reactions does not formally list 'strange taste in the mouth' or taste disturbance as a documented side effect.


Q: Does Pedicloryl interact with herbal supplements?

Official information specifically warns against taking Pedicloryl with other Central Nervous System (CNS) depressants. The need to inform a healthcare provider of all medicines and supplements, including herbal products, is consistent with regulatory guidance.


Q: How quickly is Pedicloryl eliminated from the body?

Pedicloryl is quickly converted into its active metabolite, trichloroethanol, which is then eliminated. The rate at which the active substance is cleared is described by its half-life, which is a documented pharmacokinetic property.


Q: Are there any specific laboratory tests that should be monitored while using Pedicloryl?

For pediatric use, official labeling requires specific monitoring of heart rate, respiratory function, and oxygen saturation. Caution is formally required for individuals with existing hepatic (liver) or renal (kidney) disorders, which may involve monitoring of organ function.


Q: What is the regulatory status of Pedicloryl in countries outside the US?

The medicine has an international classification as a sedative/hypnotic under the WHO ATC Code N05CM07. Its specific legal status is determined by local government agencies, such as the EMA in Europe, TGA in Australia, or Health Canada.


Q: What is the typical age range excluded from using Pedicloryl?

Official eligibility criteria state that the medicine is not recommended for general, routine use in children under 12 years of age. However, it may be administered as a single dose to children for specific procedural sedation.


Q: What common over-the-counter medicines have known interactions with Pedicloryl?

Official documents describe an additive CNS depressant effect with other Central Nervous System (CNS) depressants. This can include some common over-the-counter products, such as cold and flu medicines or pain relievers that contain ingredients with sedative (calming) effects.


Q: Is the onset of action of Pedicloryl different for children and adults?

Official administration instructions suggest a difference. For pediatric procedural sedation, it is specified to be given 45 to 60 minutes prior to the procedure. For adult use, the onset is generally described as being around 30 to 60 minutes before bedtime.


Q: Is there any mention of long-term side effects in the official research for Pedicloryl?

Since the drug is primarily prescribed for short-term treatment, official research does not focus on long-term safety. While specific 'long-term side effects' are not detailed, the safety profile highlights the documented risk of drug dependence associated with prolonged administration.


Q: Why is Pedicloryl often used as a short-term intervention?

Pedicloryl is indicated only for short-term use because regulatory safety documents specify that prolonged administration carries a specific, documented risk of Drug Dependence. Using it for a short duration helps to mitigate this risk.

How should Pedicloryl be stored and disposed of?

How to Store and Dispose of Pedicloryl

The storage and disposal of Pedicloryl Oral Solution (Triclofos sodium) must strictly follow regulatory mandates to maintain drug stability and ensure safety.

Storage Requirements

Pedicloryl must be stored at room temperature, with the required range being 10 C to 25 C or below 30 C. It is mandatory that the solution do not freeze and be protected away from heat and humidity in a cool and dry place. The medicine must be kept in its original container.

Safety and Disposal

For child safety, the product must be stored out of the sight and reach of children and pets. Unused or expired Pedicloryl must not be thrown into the household garbage and must be discarded according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pedicloryl found in:

A-Z Index: